moneyheap
KURA · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Kura Oncology, Inc. (KURA) stock moving?
Kura's Q3 2026 report, released after the close on Nov 10, shows strong commercial momentum for KOMZIFTI: net product revenue rose 53% quarter over quarter to $13.9M, new patient starts rose 30% to about 150, and total prescriptions rose 65% to more than 420, with majority share of new patient starts in the menin inhibitor class maintained. Total Q3 revenue was $22.8M, up 10% year over year, and EPS improved to $(0.78) from $(0.85). Cash, equivalents and short-term investments were $492.1M, with runway said to extend beyond the 2028 KOMET-017 topline readout. Management kept FY27 and FY28 collaboration revenue guidance at $90M-$110M each, while FY26 collaboration revenue is guided to $40M-$45M, and FDA alignment was reached on a roughly 40-patient darlifarnib study in HRAS-mutated salivary gland cancer with initiation targeted for 1H 2027. Against this, Kura filed a shelf prospectus with the size undisclosed and has up to $300M of additional financing capacity from Oberland Capital, so dilution is a live risk. The price moved sharply lower on Nov 4, falling from $9.88 to $7.61 (about -23%) on 8.2M shares, roughly four times the prior sessions' volume, but the provided news does not identify the cause. The stock has since traded between $6.76 and $7.86 and closed at $7.57 on Nov 10, so the results' market reaction is not yet in the price data.
News behind the analysis
- Kura Oncology Reports Third Quarter 2026 Financial ResultsKura reported Q3 2026 results and a corporate update, highlighting KOMZIFTI's commercial growth and FDA alignment on a darlifarnib salivary gland study.
- Kura Oncology Q3 KOMZIFTI Net Product Rev $13.9M, Up 53% Q/QKOMZIFTI net product revenue reached $13.9M in Q3, a 53% increase from the prior quarter.
- Kura Oncology Q3 KOMZIFTI New Patient Starts ~150, Up 30% Q/Q; Total Prescriptions 420+, Up 65% Q/QNew patient starts rose about 30% to roughly 150 and total prescriptions rose 65% to over 420 quarter over quarter.
- Kura Oncology Q3 Cash, Equivalents & ST Investments $492.1M; Says Cash Runway Extends Beyond KOMET-017 Topline Results In 2028Kura ended Q3 with $492.1M in cash, equivalents and short-term investments and says its runway extends beyond the 2028 KOMET-017 topline readout.
- Kura Oncology Files Shelf Prospectus For Offering; Size Not DisclosedKura filed a shelf prospectus for a future offering, but the size has not been disclosed, which raises potential dilution risk.
- Kura Oncology Sees FY26 Collaboration Rev $40M-$45M; Maintains FY27, FY28 Collaboration Rev Guidance Of $90M-$110M EachKura expects FY26 collaboration revenue of $40M-$45M and kept its FY27 and FY28 collaboration revenue guidance of $90M-$110M each.
- Kura Oncology Q3: EPS $(0.78) vs $(0.85) Prior; Rev $22.839M vs $20.750M Prior, Up 10% Y/YQ3 EPS was $(0.78) versus $(0.85) a year earlier, and revenue was $22.8M, up 10% year over year.
- Kura Oncology and Kyowa Kirin Announce Acceptance of Eight Abstracts for 2026 ASH Annual MeetingEight ziftomenib abstracts were accepted for presentation at the 2026 ASH Annual Meeting, including two oral presentations on FLT3 inhibitor combinations.
- Reported Earlier: Kura Oncology And Kyowa Kirin To Present Eight Ziftomenib Abstracts At ASH 2026, Highlighting Promising AML Combination Data And Expanded Clinical PotentialBenzinga repeated coverage of the eight accepted ziftomenib abstracts for the ASH 2026 meeting.
- Kura Oncology to Report Third Quarter 2026 Financial Results on November 10Kura announced it would release Q3 2026 results after the market close on November 10, 2026.
About Kura Oncology, Inc.
Kura Oncology is a San Diego biotech company that makes targeted cancer drugs. Its first approved product is KOMZIFTI (ziftomenib), the first FDA-approved menin inhibitor taken orally once a day, for adults whose NPM1-mutated acute myeloid leukemia (AML) has come back or stopped responding to treatment. The FDA approved it in November 2025.
How it makes money
Most of its revenue comes from US sales of KOMZIFTI, which began in late November 2025. Net product revenue was roughly $5.8 million in Q1 2026 and $9.1 million in Q2 2026. It also receives collaboration payments from its ziftomenib partnership with Kyowa Kirin, with about $180 million in future payments expected. The company still spends more than it earns and funds itself from its cash, about $519 million as of mid-2026.
What usually moves KURA
- KOMZIFTI sales growth and number of new patients starting treatment
- Trial results for ziftomenib in combination therapies and earlier (frontline) AML treatment
- Competition from other menin inhibitors such as Syndax's Revuforj
- FDA decisions and safety findings (e.g., differentiation syndrome)
- How fast it uses cash and whether it needs to raise more money